Clinical trials: Vascular Thrombosis
Pulmonary Embolism
Electronic Support for Pulmonary Embolism Emergency Disposition
To evaluate the impact of an integrated electronic clinical decision support system to facilitate risk stratification and site-of-care decision-making for patients with acute pulmonary embolism.
- Trial name
- eSPEED (NCT03601676)
- Testing
- Integration of electronic clinical decision support
- Where
- 14 sites in United States
- Volunteers
- 1,703 people
- Sponsor
- Kaiser Permanente
Terminal Cancer
Towards Cancer Patient Empowerment for Optimal Use of Antithrombotic Therapy at the End of Life
Despite the fact that antithrombotic therapy (ATT) has little or even negative effects on the well-being of cancer patients during their last year of life, stopping ATT is rare in clinical practice.
- Trial name
- SERENITY (NCT05706740)
- Testing
- Physician survey on antithrombotic medication during end-of-life care in cancer patients
- Where
- 12 sites in Denmark, France and 6 more
- Volunteers
- 467 people, healthy volunteers welcome
- Sponsor
- Johannes Gutenberg University Mainz
Deep Venous Thrombosis, Colonic Cancer
Chemoprophylaxis With Rivaroxaban for Lower Limb Deep Vein Thrombosis in Colorectal Cancer
The chemoprophylaxis of deep vein thrombosis (DVT) with subcutaneous low-molecular-weight heparin (enoxaparin) in the postoperative period of elective surgeries is already well established in the literature and in clinical…
- Trial name
- Ésquilo (NCT05303818)
- Testing
- Rivaroxaban 10 MG
- Where
- Brazil
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Hospital do Servidor Publico Estadual
Obstructive Sleep Apnea, Venous Thrombosis
Obstructive Sleep Apnea and Venous Thromboembolism
There is a clear link between obstructive sleep apnea (OSA) and cardiovascular disease. However, there has been no clear link between OSA and venous thromboembolism (VTE). The objective of this study is to evaluate such a link.
- Conditions
- Obstructive Sleep Apnea, Venous Thrombosis, Pulmonary Embolism, Venous Thromboembolism
- Trial name
- OSAVTE (NCT01051297)
- Volunteers
- 85 people
- Sponsor
- University of Missouri-Columbia
Deep Vein Thrombosis
Whole-leg Ultrasound in Pregnant Patients
This study seeks to determine the rate of thromboembolic complications (blood clots), including death attributed to thromboembolic disease, when anticoagulation (blood thinner) therapy is withheld from pregnant patients suspected…
- Trial name
- CLOT-3 (NCT01319474)
- Testing
- Whole-leg compression ultrasound
- Where
- United States
- Volunteers
- 268 people
- Sponsor
- Intermountain Health Care, Inc.
Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT)
Cancer Venous Thromboembolism (VTE)
The primary objective is to demonstrate the non-inferiority of edoxaban (preceded by a short course of LMWH) compared with dalteparin for the prevention of the combined outcome of recurrent venous thromboembolism (VTE) or major…
- Conditions
- Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Cancer
- Trial name
- NCT02073682
- Testing
- Edoxaban, Dalteparin, Low molecular weight heparin
- Where
- 9 sites in United States, Belgium and 4 more
- Volunteers
- 1,046 people
- Sponsor
- Daiichi Sankyo
Aortic Stenosis
Femoral vs Radial Approach and MRI Evaluation of Strokes
Symptomatic cerebral infarction following cardiac catheterization is rare but silent brain injury could occur at an unexpectedly high rate.
- Trial name
- NCT00329979
- Testing
- vascular access site
- Where
- France
- Volunteers
- 152 people
- Sponsor
- University Hospital, Caen
Thromboses, Deep Vein, Surgery--Complications
Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Comparison Between Rivaroxaban and Enoxaparin
The main objective is to reduce the incidence of venous thromboembolism (VTE) in orthopedic postoperative patients based on the potential benefit of using rivaroxaban as a monotherapy.
- Trial name
- NCT03299296
- Testing
- Rivaroxaban 10 Milligrams, Enoxaparin 40 Milligrams/0.4 Milliliters Prefilled Syringe
- Volunteers
- 100 people
- Sponsor
- Ahmed AbdelMoneim Hassan Ali
Superficial Vein Thrombosis, D-dimer
Superficial Vein Thrombosis Testing in the Emergency Department
Superficial vein thrombosis (SVT) occurs when blood in a vein directly under the skin clots. SVT causes vein tenderness, pain, and skin discolouration. Over time, the vein hardens into a firm, nontender, easily palpable lump.
- Trial name
- SVTest (NCT07671300)
- Testing
- D-dimer
- Where
- Canada
- Volunteers
- 400 people
- Sponsor
- Dr. Kerstin de Wit
Covid19, Venous Thromboembolism
Venous Thrombosis Virtual Surveillance in COVID-19
The overall goal of the VVIRTUOSO study is to determine the incidence of VTE including symptomatic DVT and PE after hospital discharge in patients with COVID-19 by implementing a pragmatic patient-centred prospective virtual VTE…
- Conditions
- Covid19, Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- VVIRTUOSO (NCT04865913)
- Testing
- Observational
- Where
- Canada
- Volunteers
- 510 people
- Sponsor
- Ottawa Hospital Research Institute
Prediabetic State, Metabolic Syndrome
Effects of Sweetener Consumption on Risk Factors for Heart Disease in Prediabetic Subjects
The aim of this prospective interventional study is to investigate the metabolic effects of consuming artificial and natural sweeteners in persons with prediabetes.
- Conditions
- Prediabetic State, Metabolic Syndrome, Insulin Resistance, Thrombosis
- Trial name
- Sweetheart (NCT07377097)
- Testing
- Saccharin, Sucralose, Erythritol
- Volunteers
- 80 people
- Sponsor
- Charite University, Berlin, Germany
Blood Coagulation Disorders, Venous Thromboembolism
Monitoring Trends in Venous Thromboembolism
To describe time trends in the epidemiology of venous thromboembolism.
- Conditions
- Blood Coagulation Disorders, Venous Thromboembolism, Cardiovascular Diseases
- Trial name
- NCT00063518
- Sponsor
- University of Massachusetts, Worcester
Atrial Fibrillation, Stroke Prevention in Patients With Atrial Fibrillation
CLOT-LESS - CLOsure Tailored: LEss Antithrombotic Strategy After LAAC for Stroke Prevention
This is a prospective, non-randomized, observational cohort study conducted at the FSBI "NMRC TPM" of the Ministry of Healthcare of the Russian Federation.
- Conditions
- Atrial Fibrillation, Stroke Prevention in Patients With Atrial Fibrillation, Left Atrial Appendage Closure, Hemorrhage
- Trial name
- CLOT-LESS (NCT07575867)
- Testing
- Left Atrial Appendage Closure, Apixaban 2.5 mg BID, Standard-dose DOAC
- Where
- Russia
- Volunteers
- 464 people
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
Trauma
Pragmatic, Randomized Optimal Platelet and Plasma Ratios
Pragmatic, Randomized, Optimal Platelet and Plasma Ratios (PROPPR)is a Phase III trial designed to evaluate the difference in 24-hour and 30-day mortality among subjects predicted to receive massive transfusion ([MT] (defined as…
- Trial name
- PROPPR (NCT01545232)
- Testing
- 1:1:1 Blood Transfusion Ratio, 1:1:2 Blood Transfusion Ratio
- Where
- 12 sites in United States, Canada
- Volunteers
- 680 people
- Sponsor
- The University of Texas Health Science Center, Houston
Laminectomy
Hemostatic Effect of Various Colloid Solutions
Background: Individuals with type O blood have reduced factor VIII and von Willebrand factor levels compared to the non-O counterpart.
- Trial name
- NCT00518544
- Testing
- administration of hydroxyehtyl starch
- Where
- South Korea
- Sponsor
- Samsung Medical Center
Retinal Vein Occlusion
Minocycline to Treat Central Retinal Vein Occlusion
Background: Central retinal vein occlusion (CRVO) is a blockage of the main vein that carries blood away from the retina in the back of the eye.
- Trial name
- NCT01468844
- Testing
- Minocycline, Bevacizumab
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 6 people
- Sponsor
- National Eye Institute (NEI)
Coronary Artery Stenosis, Coronary Arteriosclerosis
XIENCE V: SPIRIT WOMEN Sub-study
The purpose of this Clinical Evaluation is the continued assessment of the XIENCE Everolimus Eluting Coronary Stent System (XIENCE V® and XIENCE PRIME™ EECSS) with the primary focus on clinical outcomes in the treatment of female…
- Conditions
- Coronary Artery Stenosis, Coronary Arteriosclerosis, Coronary Artery Disease, Coronary Artery Restenosis
- Trial name
- NCT01182428
- Testing
- XIENCE V®/ XIENCE PRIME™, CYPHER SELECT
- Where
- 25 sites in Argentina, Austria and 13 more
- Volunteers
- 455 people
- Sponsor
- Abbott Medical Devices
Venous Thromboembolism, Arthroplasty, Replacement, Hip
A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery
The purpose of this study is to evaluate the efficacy and safety of various doses of YM150 (the experimental drug) compared to enoxaparin in the prevention of venous thromboembolism in patients that are undergoing elective hip…
- Trial name
- ONYX-3 (NCT00902928)
- Testing
- YM150, enoxaparin
- Where
- 156 sites in United States, Australia and 26 more
- Volunteers
- 1,992 people
- Sponsor
- Astellas Pharma Europe B.V.
Cancer, Solid Tumor
Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms
This study aims to assess biomarkers and their related polymorphisms in the context of cancer-associated thromboembolism, with a particular focus on their interaction with the immune system.
- Conditions
- Cancer, Solid Tumor, Thromboembolism, Cardiovascular Diseases
- Trial name
- CAT_PB (NCT06065592)
- Testing
- Palbociclib, Rivaroxaban, SNP
- Where
- 2 sites in Lebanon
- Volunteers
- 500 people
- Sponsor
- Lebanese University
Heart Failure, Respiratory Insufficiency
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
The purpose of this study is to evaluate the efficacy and safety of rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) events and VTE-related death post-hospital discharge in…
- Conditions
- Heart Failure, Respiratory Insufficiency, Stroke Acute, Infectious Diseases
- Trial name
- MARINER (NCT02111564)
- Testing
- Rivaroxaban, 10 mg, Rivaroxaban, 7.5 mg
- Where
- 593 sites in United States, Argentina and 35 more
- Volunteers
- 12,024 people
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.